Self-assessment of negative symptoms – Critical appraisal of the motivation and pleasure – Self-report's (MAP-SR) validity and reliability

Richter, Janina; Hesse, Klaus; Eberle, Mark-Christian; Eckstein, Kathrin N.; Zimmermann, Lina; Schreiber, Lisa; Burmeister, Carolin P.; Wildgruber, Dirk; Klingberg, Stefan

doi:10.1016/j.comppsych.2018.10.007

Cited by 7 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This scale presents good psychometric properties [158] and has been translated and validated into German [166] and Korean [167]. However, it only focuses on the motivation/pleasure dimension and if it is adequate to assess anhedonia it might be less suitable when assessing motivation [168]. Moreover, the evaluation contains many questions like "how often" and "how much", which require that patients remember and quantify what feelings or events happened in the past week, potentially difficult for patients with memory impairment.…”

Section: Scales Based On Self-assessmentsmentioning

confidence: 99%

EPA guidance on assessment of negative symptoms in schizophrenia

et al. 2021

View full text Add to dashboard Cite

Background. During the last decades, a renewed interest for negative symptoms (NS) was brought about by the increased awareness that they interfere severely with real-life functioning, particularly when they are primary and persistent. Methods. In this guidance paper, we provide a systematic review of the evidence and elaborate several recommendations for the conceptualization and assessment of NS in clinical trials and practice. Results. Expert consensus and systematic reviews have provided guidance for the optimal assessment of primary and persistent negative symptoms; second-generation rating scales, which provide a better assessment of the experiential domains, are available; however, NS are still poorly assessed both in research and clinical settings. This European Psychiatric Association (EPA) guidance recommends the use of persistent negative symptoms (PNS) construct in the context of clinical trials and highlights the need for further efforts to make the definition of PNS consistent across studies in order to exclude as much as possible secondary negative symptoms. We also encourage clinicians to use secondgeneration scales, at least to complement first-generation ones. The EPA guidance further recommends the evidence-based exclusion of several items included in first-generation scales from any NS summary or factor score to improve NS measurement in research and clinical settings. Self-rated instruments are suggested to further complement observer-rated scales in NS assessment. Several recommendations are provided for the identification of secondary negative symptoms in clinical settings. Conclusions. The dissemination of this guidance paper may promote the development of national guidelines on negative symptom assessment and ultimately improve the care of people with schizophrenia.

show abstract

Section: Scales Based On Self-assessmentsmentioning

confidence: 99%

EPA guidance on assessment of negative symptoms in schizophrenia

et al. 2021

View full text Add to dashboard Cite

show abstract

“…26,52 The evaluation of symptoms through self-report is important in psychiatric disorders and often neglected in clinical judgments. 54,55 Further to the characterization of the neurobiology of clinical phenotypes, there is also a need to identify associations between specific treatment outcomes and neurobiological changes in psychiatric patients. Clinical studies that utilize consistent methods to examine brain-behavior changes across multiple treatment groups (as opposed to single treatment studies), would facilitate the identification of beneficial medications to specific patient subgroups.…”

Section: Conceptualizing Rdocmentioning

confidence: 99%

Precision psychiatry and Research Domain Criteria: Implications for clinical trials and future practice

Williams,

Carpenter,

Carretta

et al. 2023

CNS Spectr.

View full text Add to dashboard Cite

Psychiatric disorders are associated with significant social and economic burdens, many of which are related to issues with current diagnosis and treatments. The coronavirus (COVID-19) pandemic is estimated to have increased the prevalence and burden of major depressive and anxiety disorders, indicating an urgent need to strengthen mental health systems globally. To date, current approaches adopted in drug discovery and development for psychiatric disorders have been relatively unsuccessful. Precision psychiatry aims to tailor healthcare more closely to the needs of individual patients and, when informed by neuroscience, can offer the opportunity to improve the accuracy of disease classification, treatment decisions, and prevention efforts. In this review, we highlight the growing global interest in precision psychiatry and the potential for the National Institute of Health-devised Research Domain Criteria (RDoC) to facilitate the implementation of transdiagnostic and improved treatment approaches. The need for current psychiatric nosology to evolve with recent scientific advancements and increase awareness in emerging investigators/clinicians of the value of this approach is essential. Finally, we examine current challenges and future opportunities of adopting the RDoC-associated translational and transdiagnostic approaches in clinical studies, acknowledging that the strength of RDoC is that they form a dynamic framework of guiding principles that is intended to evolve continuously with scientific developments into the future. A collaborative approach that recruits expertise from multiple disciplines, while also considering the patient perspective, is needed to pave the way for precision psychiatry that can improve the prognosis and quality of life of psychiatric patients.

show abstract

“…Notably, existing work suggests that the convergent validity or strength of the relationship between self-reported and clinician-rated motivation measures is variable (Engel and Lincoln, 2017; Luther et al, 2018). For example, Richter et al (2019) found small, non-significant relationships between the MAP-SR motivation items and the CAINS motivation and pleasure items and PANSS negative symptom subscale. On the other hand, Jang et al (2016) found medium, significant correlations between the MAP-SR motivation items and the PANSS amotivation subscale and PANSS negative symptom subscale (Luther et al, 2018).…”

Section: Introductionmentioning

confidence: 96%

Metacognition moderates the relationship between self-reported and clinician-rated motivation in schizophrenia

Luther

Bonfils

Fischer

et al. 2020

Schizophrenia Research: Cognition

View full text Add to dashboard Cite

IntroductionPrior work has found varied relationships between self-reported and clinician-rated motivation measures in schizophrenia, suggesting that moderators might impact the strength of this relationship. This current study sought to identify whether metacognition – the ability to form complex representations about oneself, others, and the world – moderates the relationship between self-reported and clinician-rated motivation measures. We also explored whether clinical insight and neurocognition moderated this relationship.MethodsFifty-six participants with a schizophrenia-spectrum disorder completed the Motivation and Pleasure Self-Report Scale and the clinician-rated motivation index from the Heinrichs-Carpenter Quality of Life Scale.ResultsMetacognition significantly moderated the relationship; self-reported and clinician-rated motivation were positively and significantly correlated only when metacognition was relatively high. Neither clinical insight nor neurocognition moderated the relationship.DiscussionMetacognition appears to be a key variable impacting the strength of the relationship between self-reported and clinician-rated motivation measures and may help to partly explain the varied relationships observed in prior work. Using a metacognitive framework to guide assessment interviews and targeting metacognition in psychosocial treatments may help to improve the synchrony between self-perceptions and clinician ratings of motivation.

show abstract

Self-assessment of negative symptoms – Critical appraisal of the motivation and pleasure – Self-report's (MAP-SR) validity and reliability

Cited by 7 publications

References 25 publications

EPA guidance on assessment of negative symptoms in schizophrenia

EPA guidance on assessment of negative symptoms in schizophrenia

Precision psychiatry and Research Domain Criteria: Implications for clinical trials and future practice

Metacognition moderates the relationship between self-reported and clinician-rated motivation in schizophrenia

Contact Info

Product

Resources

About